In the world of radiation oncology, progress tends to be measured in millimeters and fractions of a Gray. Advances come steadily but rarely feel revolutionary. FLASH radiotherapy may be an exception.
FLASH — short for ultra-high dose rate radiotherapy — delivers radiation in a fraction of a second at dose rates hundreds of times higher than conventional treatment. The technology is still emerging, but early results have generated significant excitement in the oncology community. For patients receiving proton therapy, understanding FLASH is increasingly relevant, because proton beams are among the most technically suited platforms for delivering it.
What Makes FLASH Different?
Standard radiation therapy — whether photon or proton — delivers radiation at dose rates of roughly 0.1 to 0.5 Gray per second. FLASH radiotherapy delivers radiation at dose rates exceeding 40 Gray per second, sometimes completing a full treatment fraction in less than one second.
This is not just a speed difference. Early laboratory data suggests that delivering radiation this quickly produces a fundamentally different biological effect in healthy tissue: normal cells appear to be selectively protected, while tumor cells remain as sensitive to radiation as they would be under conventional delivery. This phenomenon — called the FLASH effect — has been observed in multiple animal model studies across a range of tumor types and radiation modalities.
If the FLASH effect holds up in human patients at the scale seen in preclinical studies, the implications would be significant: it could allow oncologists to safely deliver higher doses to tumors while causing even less damage to surrounding healthy tissue than today’s already-precise treatments.
Why Proton Beams Are Central to FLASH Development
Achieving FLASH dose rates is technically demanding, and not all radiation systems can do it. Proton therapy machines — particularly those using Pencil Beam Scanning (PBS) — are among the most capable platforms for FLASH delivery. The physics of proton beams allow extremely high dose rates to be achieved at the Bragg Peak, the point of maximum energy deposition within the tumor.
Several proton therapy systems are now being adapted specifically for FLASH capability. The first human treatments with proton FLASH occurred in 2020, when a patient with bone metastasis received a single FLASH fraction at the Lausanne University Hospital in Switzerland. The results — rapid pain relief with no observed toxicity — were published in Nature Medicine and sparked widespread interest in accelerating clinical trials.
Where Does FLASH Stand Clinically Right Now?
FLASH radiotherapy is still firmly in the investigational phase. Multiple clinical trials are now underway in the United States and Europe, testing proton FLASH in patients with bone metastases, brain tumors, and other solid malignancies. The ClinicalTrials.gov registry lists an expanding number of active FLASH studies, reflecting how quickly this field is advancing from preclinical hypothesis to clinical reality.
The central questions these trials aim to answer are: Does the FLASH effect — the preferential sparing of normal tissue — translate meaningfully from animals to humans? And if so, how high can doses be safely escalated? The answers will likely come over the next several years as trial data matures.
What This Means for Today’s Proton Therapy Patients
If you are considering or currently receiving proton therapy at Tennessee Oncology Proton Center, FLASH is not yet part of standard clinical practice — but it represents the direction this field is heading. The investments being made in proton therapy infrastructure today are precisely what will enable future innovations like FLASH to be deployed quickly once they achieve clinical validation.
The same precision that makes current proton therapy so effective — the Bragg Peak, PBS targeting, real-time imaging guidance — forms the physical foundation that FLASH builds on. In other words, patients receiving proton therapy today are already benefiting from the technology that will likely underpin the next major advance in radiation oncology.
Staying Ahead of the Curve
The team at Tennessee Oncology Proton Center stays at the forefront of evolving evidence in radiation oncology. Our physicians actively follow clinical trial results, attend major oncology conferences, and evaluate new treatment approaches as they mature. When FLASH becomes a validated clinical tool, our infrastructure and expertise will be positioned to bring it to patients quickly.
If you want to learn more about the future of proton therapy or discuss whether proton treatment is appropriate for your diagnosis, we invite you to schedule a consultation with our team.
